Brian McGuinness, Ph.D.
Medicinal Chemistry
Team Leader

Sixteen years experience in the design and synthesis of pharmaceuticals with proficiency in all stages of drug discovery including hit-to-lead, lead optimization and combinatorial techniques (Pharmacopeia, Inc. and Ligand Pharmaceuticals).

Skilled team leader with expertise in collaborative research and management of off-shore FTEs. Led successful collaborative projects with Merck, GSK, and BMS.

Designed and synthesized a wide variety of therapeutic molecules: kinase inhibitors, enzyme inhibitors, CNS agents, and GPCR antagonists.

Designed and synthesized multiple heterocyclic large solid-phase encoded chemical libraries which produced hit/lead compounds for over ten medicinal chemistry programs.

Designed and synthesized High-Load PEG-PS (PerSeptive Biosystems).

Published over 25 papers in the areas of drug discovery, combinatorial synthesis, peptide synthesis, solid-phase resin development, and DNA-drug interactions.

Co-inventor of over 15 patents covering CXCR3 receptor antagonists, A2A receptor antagonists, CRTH2 receptor antagonists, and combinatorial libraries.

Ph.D. in Organic Chemistry, Columbia University, New York, NY with Koji Nakanishi.

NIH Postdoctoral Fellowship, MIT, Cambridge, Mass with Peter Lansbury, Jr.